AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32423920 — intervention group
Group type: COMPARATOR
Intervention: Deltamethrin-susceptible mosquitoes
Number of subjects: 0
Study 32423920 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of individual mosquitoes by PCR-RFLP
Number of subjects: 0
Study 35892135 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation and Motor Imagery (AO+MI)
Number of subjects: 80
Study 35892135 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 80
Study 33538237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 230
Study 33538237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 32329780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Number of subjects: 171
Study 32329780 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (V-mask)
Number of subjects: 171
Study 36498561 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) treatment
Number of subjects: 32
Study 36498561 — intervention group
Group type: COMPARATOR
Intervention: Partial Plantar Fasciotomy (PPF) surgery
Number of subjects: 32
Study 32611673 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser moxibustion
Number of subjects: 392
Study 32611673 — intervention group
Group type: COMPARATOR
Intervention: Sham laser control
Number of subjects: 392
Study 35467939 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement
Number of subjects: 200
Study 35467939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversewing using 3‐0 polydioxanone (PDS) suture
Number of subjects: 200
Study 35467939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversewing using 4‐0 barbed absorbable closure device (V‐Lock)
Number of subjects: 200
Study 35467939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant glue
Number of subjects: 200
Study 35467939 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttress material
Number of subjects: 200
Study 32746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead squat
Number of subjects: 12
Study 32746728 — intervention group
Group type: COMPARATOR
Intervention: Forefoot standing
Number of subjects: 12
Study 32746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Back squat
Number of subjects: 12
Study 32746728 — intervention group
Group type: EXPERIMENTAL
Intervention: Front squat
Number of subjects: 12
Study 36043781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg single dose)
Number of subjects: 80
Study 36043781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34261738 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1075
Study 34261738 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1075
Study 33966361 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Glutathione (L-GSH)
Number of subjects: 0
Study 33966361 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro Everolimus treatment
Number of subjects: 0
Study 33966361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-GSH and Everolimus
Number of subjects: 0
Study 33966361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33754332 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange-assisted enteroscopy
Number of subjects: 110
Study 33754332 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide-insufflated enteroscopy
Number of subjects: 110
Study 32153073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 0
Study 32153073 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 0
Study 32153073 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Medical Management (CMM)
Number of subjects: 0
Study 32265143 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Enhancement (OE)
Number of subjects: 154
Study 32265143 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 154
Study 32265143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of targeted biopsies and random biopsies in OE group
Number of subjects: 154
Study 32265143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of targeted biopsies and random biopsies in acetic acid group
Number of subjects: 154
Study 32265143 — intervention group
Group type: COMPARATOR
Intervention: Image enhanced endoscopy (OE)
Number of subjects: 154
Study 616117489 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomerizine (10 mg per day)
Number of subjects: 101
Study 616117489 — intervention group
Group type: COMPARATOR
Intervention: Methylcobalamin (1500 mug per day)
Number of subjects: 101
Study 34550329 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/d
Number of subjects: 604
Study 34550329 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3/d
Number of subjects: 604
Study 34550329 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/d
Number of subjects: 604
Study 34550329 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 604
Study 34427292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 46
Study 34427292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 32989916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary care multimodal treatment program
Number of subjects: 657
Study 35444259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 12 weeks
Number of subjects: 46
Study 35183836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic boot immobilizer (BI)
Number of subjects: 12
Study 35183836 — intervention group
Group type: COMPARATOR
Intervention: Compression sock (CS)
Number of subjects: 12
Study 32006957 — intervention group
Group type: EXPERIMENTAL
Intervention: African American speakers
Number of subjects: 0
Study 32006957 — intervention group
Group type: COMPARATOR
Intervention: Caucasian American speakers
Number of subjects: 0
Study 36109819 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tunnelling for PICC placement
Number of subjects: 1694
Study 36109819 — intervention group
Group type: COMPARATOR
Intervention: Conventional PICC placement
Number of subjects: 1694
Study 33420498 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 36056374 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week nab-paclitaxel with gemcitabine
Number of subjects: 0
Study 36056374 — intervention group
Group type: EXPERIMENTAL
Intervention: sTIL-0 ≥ 60% (lymphocyte-predominant status)
Number of subjects: 0
Study 36056374 — intervention group
Group type: EXPERIMENTAL
Intervention: sTIL-0 ≤ 10%
Number of subjects: 0
Study 36056374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week sTILs ≥ 60%
Number of subjects: 0
Study 36056374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cellularity in 3-week biopsies
Number of subjects: 0
Study 34335943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (arm A)
Number of subjects: 104
Study 34335943 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus chemotherapy (arm B)
Number of subjects: 104
Study 33359062 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV subtype C and C-related recombinants
Number of subjects: 237
Study 33359062 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique recombination forms (URF) with genotype C for gag–pol and A1 for env
Number of subjects: 237
Study 35240345 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative video intervention group
Number of subjects: 132
Study 35240345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 33938290 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential left ventricular pacing (pLVP)
Number of subjects: 220
Study 33938290 — intervention group
Group type: COMPARATOR
Intervention: Standard biventricular pacing
Number of subjects: 220
Study 32570059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group (LG) - photobiomodulation (PBM) using a diode laser (660 nm, 10 J/cm2, 0.28 J per point, 40 mW for intra-oral; 810 nm, 25 J/cm2, 0.7 J per point, 40 mW for extra-oral) applied three times a week during radiotherapy.
Number of subjects: 21
Study 32570059 — intervention group
Group type: COMPARATOR
Intervention: Sham group (SG) - sham treatment with the instrument tip sealed to prevent light passage.
Number of subjects: 21
Study 32570059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group (LG) - photobiomodulation (PBM)
Number of subjects: 21
Study 35051162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided partial release of the transverse carpal ligament using an 18-G needle
Number of subjects: 155
Study 33295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: One dose (1 g) of IV‐TXA before skin incision + one dose (1.5 g) of IA‐TXA + single dose of IV‐TXA (1 g) for 3 h
Number of subjects: 300
Study 33295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Two doses of IV‐TXA (1 g) for 3 and 6 h
Number of subjects: 300
Study 33295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Three doses of IV‐TXA (1 g) for 3, 6, and 12 h
Number of subjects: 300
Study 33295133 — intervention group
Group type: COMPARATOR
Intervention: Control: No specific control group mentioned
Number of subjects: 300
Study 35201791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 113
Study 35201791 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 113
Study 32795317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping algorithm using LTCQ-8 responses to estimate EQ-5D-5L utilities
Number of subjects: 1334
Study 32795317 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinomial response mapping model using LTCQ-8 responses
Number of subjects: 1334
Study 35854762 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined with medroxyprogesterone acetate
Number of subjects: 120
Study 35854762 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate alone (control group)
Number of subjects: 120
Study 33248904 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFibro app
Number of subjects: 40
Study 33248904 — intervention group
Group type: COMPARATOR
Intervention: Paper book
Number of subjects: 40
Study 32433138 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed models of sagittal, metopic, and bicoronal synostosis
Number of subjects: 44
Study 35191291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 25
Study 35191291 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSG)
Number of subjects: 25
Study 33960725 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1205 10 to 800 mg (single doses)
Number of subjects: 64
Study 33960725 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1205 50 mg (once daily for 14 days)
Number of subjects: 64
Study 33960725 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1205 250 mg loading dose followed by 50 mg once daily for 13 days (open-label part)
Number of subjects: 64
Study 33960725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32386000 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg orally every night for 4 weeks
Number of subjects: 40
Study 32386000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group with atorvastatin and subcutaneous injection of 140 mg evolocumab every 2 weeks for 4 weeks
Number of subjects: 40
Study 33594695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) nurse‐coordinated transitional care intervention
Number of subjects: 153
Study 33050910 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT with concurrent systemic therapies (ST) including chemotherapy, immunotherapy, targeted therapy, and hormonotherapy.
Number of subjects: 99
Study 33050910 — intervention group
Group type: COMPARATOR
Intervention: SRT alone without concurrent ST.
Number of subjects: 99
Study 35618375 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity coaching
Number of subjects: 151
Study 35618375 — intervention group
Group type: COMPARATOR
Intervention: Lower fidelity coaching
Number of subjects: 151
Study 33647518 — intervention group
Group type: EXPERIMENTAL
Intervention: BioBERT-based neural network classifiers
Number of subjects: 50
Study 33647518 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority vote and label aggregation
Number of subjects: 50
Study 33647518 — intervention group
Group type: EXPERIMENTAL
Intervention: Two rule-based methods (phrase-based and section header-based)
Number of subjects: 50
Study 33647518 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-annotator agreement
Number of subjects: 50
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 2151
Study 32676679 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2151
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2151
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomisation subgroup (longer time to shock reversal)
Number of subjects: 2151
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 2151
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 2151
Study 32676679 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (male vs female)
Number of subjects: 2151
Study 34425016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation group (PaO2 of 8 kPa)
Number of subjects: 110
Study 34425016 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation group (PaO2 of 12 kPa)
Number of subjects: 110
Study 32188478 — intervention group
Group type: COMPARATOR
Intervention: PALs
Number of subjects: 600
Study 32207735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 31
Study 32207735 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 31
Study 35835210 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 57
Study 35835210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 33782086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention)
Number of subjects: 1729
Study 33782086 — intervention group
Group type: COMPARATOR
Intervention: Standard micronutrient supplement (control)
Number of subjects: 1729
Study 32169689 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued escitalopram treatment
Number of subjects: 180
Study 32169689 — intervention group
Group type: COMPARATOR
Intervention: Switch to bupropion (blinded control condition)
Number of subjects: 180
Study 35675076 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atogepant
Number of subjects: 902
Study 35675076 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of atogepant
Number of subjects: 902
Study 35675076 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of atogepant
Number of subjects: 902
Study 35675076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902
Study 34848313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (HES)
Number of subjects: 70
Study 34848313 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 70
Study 35081832 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS-guided cannulation
Number of subjects: 13
Study 35081832 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation
Number of subjects: 13
Study 33661911 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning analysis with radiomics features and APCT (training cohort)
Number of subjects: 500
Study 33661911 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning analysis with radiomics features and APCT (validation cohort)
Number of subjects: 500
Study 32686958 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad-score based on four characteristic parameters (ClusterShade_AllDirection_offset4_SD, ShortRunEmphasis_angle45_offset1, Maximum3DDiameter, SurfaceVolumeRatio)
Number of subjects: 89
Study 35274326 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus standard therapy (hydroxychloroquine + Kaletra®)
Number of subjects: 156
Study 35274326 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (hydroxychloroquine + Kaletra®)
Number of subjects: 156
Study 33287829 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) strategy
Number of subjects: 206
Study 33287829 — intervention group
Group type: COMPARATOR
Intervention: Machine learning (ML) algorithm
Number of subjects: 206
Study 35199483 — intervention group
Group type: EXPERIMENTAL
Intervention: S-flurbiprofen plaster (SFPP)
Number of subjects: 311
Study 35199483 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel
Number of subjects: 311
Study 33498953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min)
Number of subjects: 41
Study 35666889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective therapy (ND)
Number of subjects: 59
Study 35666889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 59
Study 35666889 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 59
Study 35666889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden losses (SLs) and reversals
Number of subjects: 59
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior and anterolateral approaches
Number of subjects: 372
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteversion angles ≥ 25°
Number of subjects: 372
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclination angles ≥ 50°
Number of subjects: 372
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: UHMWPE‐X and UHMWPE‐XE liners
Number of subjects: 372
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup positioning outside the Lewinnek safe zone
Number of subjects: 372
Study 35397656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean anteversion
Number of subjects: 372
Study 35641950 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing condition (communication training)
Number of subjects: 192
Study 35641950 — intervention group
Group type: COMPARATOR
Intervention: Negative framing condition (statistics seminar)
Number of subjects: 192
Study 35641950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 192
Study 33066811 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based synchronous finger tapping (SFT) intervention for 25 minutes daily for 8 weeks
Number of subjects: 0
Study 33066811 — intervention group
Group type: COMPARATOR
Intervention: Control arm (details not specified)
Number of subjects: 0
Study 34895700 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of relugolix (REL) orally once a day for 24 weeks
Number of subjects: 0
Study 34895700 — intervention group
Group type: COMPARATOR
Intervention: 3.75 or 1.88 mg of leuprorelin (LEU) subcutaneously every 4 weeks for 24 weeks
Number of subjects: 0
Study 34895700 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of relugolix (REL)
Number of subjects: 0
Study 34895700 — intervention group
Group type: COMPARATOR
Intervention: 3.75 or 1.88 mg of leuprorelin (LEU)
Number of subjects: 0
Study 33738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniotomy (DCO)
Number of subjects: 208
Study 33738561 — intervention group
Group type: COMPARATOR
Intervention: Decompressive craniectomy (DC)
Number of subjects: 208
Study 33738561 — intervention group
Group type: EXPERIMENTAL
Intervention: DCO techniques
Number of subjects: 208
Study 33738561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in randomized trial
Number of subjects: 208
Study 34028361 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Number of subjects: 128
Study 34028361 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 128
Study 32931661 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 11345
Study 35637595 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention (education/promotional messages)
Number of subjects: 8992
Study 35637595 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental intervention (chilled water station)
Number of subjects: 8992
Study 35637595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 8992
Study 35637595 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 8992
Study 34105207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day; days 1–14; 21 days per cycle)
Number of subjects: 419
Study 34105207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 32281941 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention supported by a mobile health app
Number of subjects: 67
Study 32281941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app
Number of subjects: 67
Study 32281941 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 35570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Mindfulness Based Cognitive Therapy (tele-MBCT), 8 weekly live online sessions, average daily practice of 23.58±45.71 minutes.
Number of subjects: 26
Study 35570513 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 26
Study 33599270 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to a PI-based second-line regimen
Number of subjects: 80
Study 33599270 — intervention group
Group type: COMPARATOR
Intervention: Continue on first-line therapy (control)
Number of subjects: 80
Study 32947459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Vaseline (applied to nonlesional skin of one forearm)
Number of subjects: 20